Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Biologics: Targets and Therapy is Scopus-indexed (Q2, CiteScore 4.5), WoS ESCI, DOAJ. Published by Dove Medical Press Ltd.
Checked against the index lists dated .
ISSN 1177-5475Verify ISSN ↗1177-5491Verify ISSN ↗
Publisher: Dove Medical Press Ltd
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Gastroenterology | 58 / 176 | 67th | Q2 |
| Rheumatology | 29 / 77 | 62nd | Q2 |
| Pharmacology (medical) | 117 / 278 | 58th | Q2 |
| Oncology | 187 / 428 | 56th | Q2 |
| Immunology and Allergy | 125 / 234 | 46th | Q3 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2007–present (also 1988), best quartile Q2, CiteScore 4.5.
Biologics: Targets and Therapy is Q2 in Gastroenterology (rank 58 of 176), Q2 in Rheumatology (rank 29 of 77) and Q2 in Pharmacology (medical) (rank 117 of 278), by CiteScore 2025. It is ranked in 5 subject areas in all.
Biologics: Targets and Therapy is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 4.5, which places it in quartile Q2 at the 67th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.989, quartile Q1, with an H-index of 53.
The publisher lists an article processing charge of about US$2,320 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Biologics: Targets and Therapy is published by Dove Medical Press Ltd. Its print ISSN is 1177-5475 and its online ISSN is 1177-5491.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
Biologics: Targets and Therapy has an h-index of 58 and a 2-year mean of 4.13 citations per paper (OpenAlex). Its Scopus CiteScore is 4.5, quartile Q2. On 2-year citations it ranks #16 of 172 Scopus journals in Gastroenterology.
Biologics: Targets and Therapy published 56 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 98 research articles (2024–2026), authors are most often from China (37.9%), United States (9.9%) and Italy (5.8%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 4 retracted papers are recorded (6.6 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.